HUTCHMED (China) Limited

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ZTS has a market cap of 68.3B. Regarding current trading prices, HCM is priced at $15.87, while ZTS trades at $153.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ZTS's P/E ratio is 26.48. In terms of profitability, HCM's ROE is +0.05%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, HCM is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZTS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TAK has a market cap of 47.5B. Regarding current trading prices, HCM is priced at $15.87, while TAK trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TAK's P/E ratio is 51.71. In terms of profitability, HCM's ROE is +0.05%, compared to TAK's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check TAK's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, HLN has a market cap of 43.7B. Regarding current trading prices, HCM is priced at $15.87, while HLN trades at $9.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas HLN's P/E ratio is 21.43. In terms of profitability, HCM's ROE is +0.05%, compared to HLN's ROE of +0.09%. Regarding short-term risk, HCM is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check HLN's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TEVA has a market cap of 20.3B. Regarding current trading prices, HCM is priced at $15.87, while TEVA trades at $17.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TEVA's P/E ratio is -119.00. In terms of profitability, HCM's ROE is +0.05%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TEVA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HCM is priced at $15.87, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HCM's ROE is +0.05%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, HCM is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ITCI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, NBIX has a market cap of 13.2B. Regarding current trading prices, HCM is priced at $15.87, while NBIX trades at $131.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas NBIX's P/E ratio is 39.44. In terms of profitability, HCM's ROE is +0.05%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, HCM is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check NBIX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, VTRS has a market cap of 12.4B. Regarding current trading prices, HCM is priced at $15.87, while VTRS trades at $10.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas VTRS's P/E ratio is -3.62. In terms of profitability, HCM's ROE is +0.05%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, HCM is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VTRS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, RDY has a market cap of 11.8B. Regarding current trading prices, HCM is priced at $15.87, while RDY trades at $14.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas RDY's P/E ratio is 18.23. In terms of profitability, HCM's ROE is +0.05%, compared to RDY's ROE of +0.17%. Regarding short-term risk, HCM is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RDY's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HCM is priced at $15.87, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HCM's ROE is +0.05%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, HCM is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CTLT's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ELAN has a market cap of 8.9B. Regarding current trading prices, HCM is priced at $15.87, while ELAN trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ELAN's P/E ratio is 20.40. In terms of profitability, HCM's ROE is +0.05%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, HCM is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ELAN's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, RGC has a market cap of 6.5B. Regarding current trading prices, HCM is priced at $15.87, while RGC trades at $12.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas RGC's P/E ratio is -1312.00. In terms of profitability, HCM's ROE is +0.05%, compared to RGC's ROE of -0.50%. Regarding short-term risk, HCM is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RGC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, LNTH has a market cap of 3.7B. Regarding current trading prices, HCM is priced at $15.87, while LNTH trades at $54.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas LNTH's P/E ratio is 14.41. In terms of profitability, HCM's ROE is +0.05%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, HCM is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNTH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PRGO has a market cap of 3.1B. Regarding current trading prices, HCM is priced at $15.87, while PRGO trades at $23.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PRGO's P/E ratio is -52.81. In terms of profitability, HCM's ROE is +0.05%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, HCM is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PRGO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, HCM is priced at $15.87, while BHC trades at $7.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BHC's P/E ratio is 32.10. In terms of profitability, HCM's ROE is +0.05%, compared to BHC's ROE of -0.09%. Regarding short-term risk, HCM is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BHC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AMRX has a market cap of 3B. Regarding current trading prices, HCM is priced at $15.87, while AMRX trades at $9.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AMRX's P/E ratio is 945.00. In terms of profitability, HCM's ROE is +0.05%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, INDV has a market cap of 2.9B. Regarding current trading prices, HCM is priced at $15.87, while INDV trades at $23.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas INDV's P/E ratio is 28.96. In terms of profitability, HCM's ROE is +0.05%, compared to INDV's ROE of -0.48%. Regarding short-term risk, HCM is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INDV's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ALVO has a market cap of 2.4B. Regarding current trading prices, HCM is priced at $15.87, while ALVO trades at $8.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ALVO's P/E ratio is 34.89. In terms of profitability, HCM's ROE is +0.05%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, HCM is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ALVO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, HCM is priced at $15.87, while ALVOW trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ALVOW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.05%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, HCM is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ALVOW's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SUPN has a market cap of 2.4B. Regarding current trading prices, HCM is priced at $15.87, while SUPN trades at $42.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SUPN's P/E ratio is 37.12. In terms of profitability, HCM's ROE is +0.05%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, HCM is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SUPN's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HCM is priced at $15.87, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HCM's ROE is +0.05%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HCM is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DCPH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HCM is priced at $15.87, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.05%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, HCM is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBCV's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ANIP has a market cap of 1.9B. Regarding current trading prices, HCM is priced at $15.87, while ANIP trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ANIP's P/E ratio is -126.74. In terms of profitability, HCM's ROE is +0.05%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ANIP's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HCM is priced at $15.87, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TARO's P/E ratio is 30.05. In terms of profitability, HCM's ROE is +0.05%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HCM is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check TARO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BGM has a market cap of 1.5B. Regarding current trading prices, HCM is priced at $15.87, while BGM trades at $7.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BGM's P/E ratio is -26.14. In terms of profitability, HCM's ROE is +0.05%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BGM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, HCM is priced at $15.87, while HROW trades at $40.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas HROW's P/E ratio is -138.64. In terms of profitability, HCM's ROE is +0.05%, compared to HROW's ROE of -0.18%. Regarding short-term risk, HCM is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HROW's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, HCM is priced at $15.87, while AMPH trades at $30.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AMPH's P/E ratio is 11.17. In terms of profitability, HCM's ROE is +0.05%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, HCM is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMPH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, HCM is priced at $15.87, while EVO trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EVO's P/E ratio is -7.37. In terms of profitability, HCM's ROE is +0.05%, compared to EVO's ROE of -0.22%. Regarding short-term risk, HCM is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EVO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AVDL has a market cap of 1.3B. Regarding current trading prices, HCM is priced at $15.87, while AVDL trades at $13.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AVDL's P/E ratio is -684.50. In terms of profitability, HCM's ROE is +0.05%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, HCM is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AVDL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, HCM is priced at $15.87, while DVAX trades at $10.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas DVAX's P/E ratio is -23.98. In terms of profitability, HCM's ROE is +0.05%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, HCM is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check DVAX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $15.87, while PAHC trades at $30.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PAHC's P/E ratio is 39.32. In terms of profitability, HCM's ROE is +0.05%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, HCM is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PAHC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $15.87, while COLL trades at $37.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas COLL's P/E ratio is 35.60. In terms of profitability, HCM's ROE is +0.05%, compared to COLL's ROE of +0.19%. Regarding short-term risk, HCM is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COLL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TLRY has a market cap of 1.1B. Regarding current trading prices, HCM is priced at $15.87, while TLRY trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TLRY's P/E ratio is -0.42. In terms of profitability, HCM's ROE is +0.05%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, HCM is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLRY's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, HCM is priced at $15.87, while PCRX trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PCRX's P/E ratio is -9.01. In terms of profitability, HCM's ROE is +0.05%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, HCM is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PCRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HCM is priced at $15.87, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HCM's ROE is +0.05%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, HCM is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PETQ's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CRON has a market cap of 907.6M. Regarding current trading prices, HCM is priced at $15.87, while CRON trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CRON's P/E ratio is 47.40. In terms of profitability, HCM's ROE is +0.05%, compared to CRON's ROE of +0.02%. Regarding short-term risk, HCM is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRON's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EMBC has a market cap of 800.7M. Regarding current trading prices, HCM is priced at $15.87, while EMBC trades at $13.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EMBC's P/E ratio is 9.64. In terms of profitability, HCM's ROE is +0.05%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, HCM is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SIGA has a market cap of 608.7M. Regarding current trading prices, HCM is priced at $15.87, while SIGA trades at $8.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SIGA's P/E ratio is 7.46. In terms of profitability, HCM's ROE is +0.05%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, HCM is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SIGA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ORGO has a market cap of 600M. Regarding current trading prices, HCM is priced at $15.87, while ORGO trades at $4.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ORGO's P/E ratio is -33.79. In terms of profitability, HCM's ROE is +0.05%, compared to ORGO's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ORGO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HCM is priced at $15.87, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HCM's ROE is +0.05%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HCM is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check BDSI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SNDL has a market cap of 519.9M. Regarding current trading prices, HCM is priced at $15.87, while SNDL trades at $2.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SNDL's P/E ratio is -7.21. In terms of profitability, HCM's ROE is +0.05%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, HCM is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNDL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EBS has a market cap of 472.7M. Regarding current trading prices, HCM is priced at $15.87, while EBS trades at $8.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EBS's P/E ratio is 3.38. In terms of profitability, HCM's ROE is +0.05%, compared to EBS's ROE of +0.27%. Regarding short-term risk, HCM is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EBS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EOLS has a market cap of 435.3M. Regarding current trading prices, HCM is priced at $15.87, while EOLS trades at $6.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EOLS's P/E ratio is -6.94. In terms of profitability, HCM's ROE is +0.05%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, HCM is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EOLS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, KMDA has a market cap of 422.7M. Regarding current trading prices, HCM is priced at $15.87, while KMDA trades at $7.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas KMDA's P/E ratio is 22.97. In terms of profitability, HCM's ROE is +0.05%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, HCM is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check KMDA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AQST has a market cap of 409.9M. Regarding current trading prices, HCM is priced at $15.87, while AQST trades at $4.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AQST's P/E ratio is -5.96. In terms of profitability, HCM's ROE is +0.05%, compared to AQST's ROE of +1.09%. Regarding short-term risk, HCM is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AQST's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ESPR has a market cap of 406.3M. Regarding current trading prices, HCM is priced at $15.87, while ESPR trades at $2.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ESPR's P/E ratio is -4.10. In terms of profitability, HCM's ROE is +0.05%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, HCM is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ESPR's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ZYBT has a market cap of 355.9M. Regarding current trading prices, HCM is priced at $15.87, while ZYBT trades at $7.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ZYBT's P/E ratio is 250.33. In terms of profitability, HCM's ROE is +0.05%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, HCM is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYBT's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HCM is priced at $15.87, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HCM's ROE is +0.05%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, HCM is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ALIM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CGC has a market cap of 295.9M. Regarding current trading prices, HCM is priced at $15.87, while CGC trades at $1.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CGC's P/E ratio is -0.42. In terms of profitability, HCM's ROE is +0.05%, compared to CGC's ROE of -0.99%. Regarding short-term risk, HCM is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CGC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ACB has a market cap of 285.7M. Regarding current trading prices, HCM is priced at $15.87, while ACB trades at $5.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ACB's P/E ratio is -127.00. In terms of profitability, HCM's ROE is +0.05%, compared to ACB's ROE of +0.00%. Regarding short-term risk, HCM is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACB's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, LFCR has a market cap of 275.7M. Regarding current trading prices, HCM is priced at $15.87, while LFCR trades at $7.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas LFCR's P/E ratio is -5.80. In terms of profitability, HCM's ROE is +0.05%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, HCM is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LFCR's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HCM is priced at $15.87, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HCM's ROE is +0.05%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, HCM is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNDC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TKNO has a market cap of 251M. Regarding current trading prices, HCM is priced at $15.87, while TKNO trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TKNO's P/E ratio is -12.03. In terms of profitability, HCM's ROE is +0.05%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, HCM is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TKNO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HCM is priced at $15.87, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HCM's ROE is +0.05%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HCM is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TYHT's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, OGI has a market cap of 191.5M. Regarding current trading prices, HCM is priced at $15.87, while OGI trades at $1.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas OGI's P/E ratio is 143.00. In terms of profitability, HCM's ROE is +0.05%, compared to OGI's ROE of +0.05%. Regarding short-term risk, HCM is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check OGI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SXTC has a market cap of 185.6M. Regarding current trading prices, HCM is priced at $15.87, while SXTC trades at $1.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SXTC's P/E ratio is -0.69. In terms of profitability, HCM's ROE is +0.05%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, HCM is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SXTC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HCM is priced at $15.87, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas REPH's P/E ratio is -8.04. In terms of profitability, HCM's ROE is +0.05%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HCM is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check REPH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, IRWD has a market cap of 167.3M. Regarding current trading prices, HCM is priced at $15.87, while IRWD trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas IRWD's P/E ratio is -20.60. In terms of profitability, HCM's ROE is +0.05%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, HCM is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IRWD's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BIOA has a market cap of 163.1M. Regarding current trading prices, HCM is priced at $15.87, while BIOA trades at $4.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BIOA's P/E ratio is -0.67. In terms of profitability, HCM's ROE is +0.05%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, HCM is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BIOA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, DERM has a market cap of 161.9M. Regarding current trading prices, HCM is priced at $15.87, while DERM trades at $7.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas DERM's P/E ratio is -18.78. In terms of profitability, HCM's ROE is +0.05%, compared to DERM's ROE of -0.49%. Regarding short-term risk, HCM is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check DERM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, THTX has a market cap of 149M. Regarding current trading prices, HCM is priced at $15.87, while THTX trades at $3.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas THTX's P/E ratio is -17.05. In terms of profitability, HCM's ROE is +0.05%, compared to THTX's ROE of +0.38%. Regarding short-term risk, HCM is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check THTX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HCM is priced at $15.87, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HCM's ROE is +0.05%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HCM is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check SCTL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PROC has a market cap of 114M. Regarding current trading prices, HCM is priced at $15.87, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PROC's P/E ratio is 1.53. In terms of profitability, HCM's ROE is +0.05%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PROC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CRDL has a market cap of 108.3M. Regarding current trading prices, HCM is priced at $15.87, while CRDL trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CRDL's P/E ratio is -3.85. In terms of profitability, HCM's ROE is +0.05%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, HCM is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRDL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HCM is priced at $15.87, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HCM's ROE is +0.05%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, HCM is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check OPTN's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HCM is priced at $15.87, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HCM's ROE is +0.05%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, HCM is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZOM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, INCR has a market cap of 89.4M. Regarding current trading prices, HCM is priced at $15.87, while INCR trades at $1.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas INCR's P/E ratio is -3.81. In terms of profitability, HCM's ROE is +0.05%, compared to INCR's ROE of -0.15%. Regarding short-term risk, HCM is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INCR's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HCM is priced at $15.87, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HCM's ROE is +0.05%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, HCM is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GRVI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ASRT has a market cap of 78.3M. Regarding current trading prices, HCM is priced at $15.87, while ASRT trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ASRT's P/E ratio is -1.81. In terms of profitability, HCM's ROE is +0.05%, compared to ASRT's ROE of -0.38%. Regarding short-term risk, HCM is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ASRT's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, QNTM has a market cap of 76.9M. Regarding current trading prices, HCM is priced at $15.87, while QNTM trades at $22.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas QNTM's P/E ratio is -1.97. In terms of profitability, HCM's ROE is +0.05%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, HCM is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check QNTM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HCM is priced at $15.87, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HCM's ROE is +0.05%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HCM is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYNE's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HCM is priced at $15.87, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HCM's ROE is +0.05%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, HCM is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SSIC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HCM is priced at $15.87, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HCM's ROE is +0.05%, compared to VLNS's ROE of N/A. Regarding short-term risk, HCM is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VLNS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HCM is priced at $15.87, while DRRX trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas DRRX's P/E ratio is -4.34. In terms of profitability, HCM's ROE is +0.05%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, HCM is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check DRRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, KALA has a market cap of 58.4M. Regarding current trading prices, HCM is priced at $15.87, while KALA trades at $8.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas KALA's P/E ratio is -1.40. In terms of profitability, HCM's ROE is +0.05%, compared to KALA's ROE of -6.86%. Regarding short-term risk, HCM is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check KALA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HCM is priced at $15.87, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HCM's ROE is +0.05%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, HCM is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check JUPW's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CPIX has a market cap of 47.1M. Regarding current trading prices, HCM is priced at $15.87, while CPIX trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CPIX's P/E ratio is -14.32. In terms of profitability, HCM's ROE is +0.05%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, HCM is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CPIX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EGRX has a market cap of 41.6M. Regarding current trading prices, HCM is priced at $15.87, while EGRX trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EGRX's P/E ratio is 3.76. In terms of profitability, HCM's ROE is +0.05%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, HCM is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check EGRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HCM is priced at $15.87, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas QLI's P/E ratio is -4.92. In terms of profitability, HCM's ROE is +0.05%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HCM is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check QLI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, RMTI has a market cap of 34.9M. Regarding current trading prices, HCM is priced at $15.87, while RMTI trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas RMTI's P/E ratio is -14.57. In terms of profitability, HCM's ROE is +0.05%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RMTI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SCYX has a market cap of 32.5M. Regarding current trading prices, HCM is priced at $15.87, while SCYX trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SCYX's P/E ratio is -2.08. In terms of profitability, HCM's ROE is +0.05%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, HCM is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SCYX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HCM is priced at $15.87, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HCM's ROE is +0.05%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HCM is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HEXO's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, COSM has a market cap of 26.2M. Regarding current trading prices, HCM is priced at $15.87, while COSM trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas COSM's P/E ratio is -0.82. In terms of profitability, HCM's ROE is +0.05%, compared to COSM's ROE of -0.51%. Regarding short-term risk, HCM is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COSM's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HCM is priced at $15.87, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HCM's ROE is +0.05%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, HCM is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CYTH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HCM is priced at $15.87, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HCM's ROE is +0.05%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, HCM is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, PRPH has a market cap of 14.3M. Regarding current trading prices, HCM is priced at $15.87, while PRPH trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas PRPH's P/E ratio is -0.17. In terms of profitability, HCM's ROE is +0.05%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, HCM is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PRPH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, FLGC has a market cap of 14M. Regarding current trading prices, HCM is priced at $15.87, while FLGC trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas FLGC's P/E ratio is -0.70. In terms of profitability, HCM's ROE is +0.05%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, HCM is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check FLGC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AYTU has a market cap of 13.6M. Regarding current trading prices, HCM is priced at $15.87, while AYTU trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AYTU's P/E ratio is -1.48. In terms of profitability, HCM's ROE is +0.05%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, HCM is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AYTU's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TXMD has a market cap of 13.5M. Regarding current trading prices, HCM is priced at $15.87, while TXMD trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TXMD's P/E ratio is -23.40. In terms of profitability, HCM's ROE is +0.05%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, HCM is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TXMD's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, GELS has a market cap of 13.3M. Regarding current trading prices, HCM is priced at $15.87, while GELS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas GELS's P/E ratio is -3.80. In terms of profitability, HCM's ROE is +0.05%, compared to GELS's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GELS's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, IXHL has a market cap of 11.2M. Regarding current trading prices, HCM is priced at $15.87, while IXHL trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas IXHL's P/E ratio is -0.31. In terms of profitability, HCM's ROE is +0.05%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, HCM is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IXHL's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HCM is priced at $15.87, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HCM's ROE is +0.05%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, HCM is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AGRX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BFRI has a market cap of 9.5M. Regarding current trading prices, HCM is priced at $15.87, while BFRI trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BFRI's P/E ratio is -1.16. In terms of profitability, HCM's ROE is +0.05%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, HCM is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BFRI's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, SNOA has a market cap of 8.8M. Regarding current trading prices, HCM is priced at $15.87, while SNOA trades at $5.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas SNOA's P/E ratio is -2.42. In terms of profitability, HCM's ROE is +0.05%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, HCM is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNOA's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, TLPH has a market cap of 8.7M. Regarding current trading prices, HCM is priced at $15.87, while TLPH trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas TLPH's P/E ratio is -0.97. In terms of profitability, HCM's ROE is +0.05%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, HCM is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLPH's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, IMCC has a market cap of 8.2M. Regarding current trading prices, HCM is priced at $15.87, while IMCC trades at $2.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas IMCC's P/E ratio is -5.43. In terms of profitability, HCM's ROE is +0.05%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, HCM is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IMCC's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HCM is priced at $15.87, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HCM's ROE is +0.05%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, HCM is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check NLTX's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, BFRIW has a market cap of 7.9M. Regarding current trading prices, HCM is priced at $15.87, while BFRIW trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas BFRIW's P/E ratio is -0.08. In terms of profitability, HCM's ROE is +0.05%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, HCM is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BFRIW's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, EVOK has a market cap of 7.6M. Regarding current trading prices, HCM is priced at $15.87, while EVOK trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas EVOK's P/E ratio is -4.16. In terms of profitability, HCM's ROE is +0.05%, compared to EVOK's ROE of -1.02%. Regarding short-term risk, HCM is less volatile compared to EVOK. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EVOK's competition here

HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HCM stands at 2.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HCM is priced at $15.87, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HCM currently has a P/E ratio of 6.21, whereas LCI's P/E ratio is -0.04. In terms of profitability, HCM's ROE is +0.05%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HCM is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LCI's competition here